食欲素、睡眠与阿尔茨海默病认知:非快速眼动振荡活动与神经韧性
该前瞻性队列研究纳入60例生物标志物确诊的轻中度阿尔茨海默病患者,发现非快速眼动睡眠纺锤波和慢振荡活动与脑脊液食欲素浓度相关,且这些振荡活动可减弱食欲素与认知及神经精神结局的不良关联。
要点
- 睡眠纺锤波密度和功率越高,脑脊液食欲素浓度越低。
- 较高食欲素水平与更差认知、更重神经精神症状及更高tau和YKL-40相关。
- 纺锤波-慢振荡活动可减弱食欲素与认知结局的不良关联。
核心结论
- 在生物标志物确诊的阿尔茨海默病中,非快速眼动睡眠纺锤波和慢振荡活动与脑脊液食欲素浓度相关,并调节食欲素与纵向认知及神经精神结局的关联。
研究设计与样本
- 前瞻性观察性队列研究,纳入60例年龄≥60岁、生物标志物确诊的轻中度阿尔茨海默病患者,在西班牙Lleida三级记忆门诊开展。
主要发现
- 较长慢振荡持续时间及较高睡眠纺锤波密度和功率与较低脑脊液食欲素浓度相关(纺锤波密度:β = -187.37 pg/mL,95% CI -344.93 至 -29.80)。
- 较高脑脊液食欲素浓度与更差全局认知相关(ADAS-Cog:β = 0.014,95% CI 0.003-0.024;MMSE:β = -0.01,95% CI -0.011 至 -0.004)。
- 较高食欲素浓度与更重神经精神症状相关(NPI:β = 0.03,95% CI 0.011-0.041)。
- 较高食欲素浓度与较高pTau181(β = 0.11,95% CI 0.04-0.19)、总tau及YKL-40(β = 0.37,95% CI 0.17-0.57)相关。
- 食欲素与睡眠纺锤波-慢振荡活动存在显著交互作用,较高振荡活动减弱食欲素与认知结局的不良关联。
临床怎么用
- 非快速眼动睡眠振荡指标和食欲素浓度可能作为阿尔茨海默病疾病监测的互补生理标志物。
- 睡眠纺锤波和慢振荡活动或可提示神经韧性,为治疗靶点提供线索。
局限性
- 观察性设计且无对照组,无法进行因果推断,也难以与正常老化进行背景比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Sleep-wake dysregulation and elevated CSF orexin have been implicated in Alzheimer disease (AD). Sleep spindles (SPs) and slow oscillations (SOs) are linked to cognition and neurodegeneration; however, their relationship with CSF orexin concentrations in symptomatic AD has not been characterized. We investigated whether nonrapid eye movement (NREM) SP-SO activity is associated with CSF orexin and whether these oscillatory features moderate associations between orexin, cognition, neuropsychiatric symptom severity, and AD biomarkers. METHODS: This prospective observational cohort study was conducted at a tertiary memory clinic in Lleida, Spain. Individuals aged ≥60 years with biomarker-confirmed mild-to-moderate AD (National Institute on Aging-Alzheimer's Association criteria) underwent overnight polysomnography and morning CSF sampling. SP and SO were detected using validated automated algorithms with independent verification and visual quality control. CSF was assayed for orexin-A, amyloid-β42 (Aβ42), phosphorylated tau181 (pTau181), total tau, and YKL-40. Cognitive performance Alzheimer's Disease Assessment Scale-Cognitive Subscale ([ADAS-Cog], Mini-Mental State Examination (MMSE), California verbal learning test, ROCF) and neuropsychiatric symptoms (NPI) were assessed longitudinally over 36 months. Associations were examined using generalized linear models with robust estimators adjusted for age, sex, Aβ42, and apnea-hypopnea index. Multiple comparisons were controlled using false discovery rate correction. Interaction terms assessed moderation effects. RESULTS: Sixty participants (30 women; mean age 74.7 years) were included. Longer SO duration and higher SP density and power were associated with lower CSF orexin concentrations (SP density: β = -187.37 pg/mL, 95% CI -344.93 to -29.80). Orexin was not associated with global sleep continuity metrics. Higher CSF orexin concentrations were associated with worse global cognition (ADAS-Cog: β = 0.014, 95% CI 0.003-0.024; MMSE: β = -0.01, 95% CI -0.011 to -0.004) and greater neuropsychiatric symptom severity (NPI at: β = 0.03, 95% CI 0.011-0.041). Higher orexin was also associated with higher pTau181 (β = 0.11, 95% CI 0.04-0.19), total tau, and YKL-40 (β = 0.37, 95% CI 0.17-0.57). Significant orexin × SP-SO interactions were observed, such that greater oscillatory activity attenuated the adverse associations between orexin and cognitive outcomes, independent of Aβ42 and tau. DISCUSSION: In biomarker-confirmed AD, NREM SP and SO activity are associated with CSF orexin concentrations and moderate associations between orexin and longitudinal cognitive and neuropsychiatric outcomes. Limitations include the observational design and absence of a comparator group, precluding causal inference and limiting contextualization relative to normal aging. NREM oscillatory metrics and orexin concentrations may represent complementary physiologic markers for disease monitoring and therapeutic targeting. TRIAL REGISTRATION INFORMATION: Role of Hypoxia and Sleep Fragmentation in AD; ClinicalTrials.gov Identifier: NCT02814045.
引用
- Paez A, Piñol-Ripoll G, Carnes-Vendrell A, et al. Orexin, Sleep, and Cognition in Alzheimer Disease: Non-REM Oscillatory Activity and Neural Resilience. Neurology. 2026. PMID: 42447420. doi:10.1212/WNL.0000000000218307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。